<SEC-DOCUMENT>0001193125-25-145242.txt : 20250624
<SEC-HEADER>0001193125-25-145242.hdr.sgml : 20250624
<ACCEPTANCE-DATETIME>20250624070520
ACCESSION NUMBER:		0001193125-25-145242
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250623
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250624
DATE AS OF CHANGE:		20250624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Revolution Medicines, Inc.
		CENTRAL INDEX KEY:			0001628171
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				472029180
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39219
		FILM NUMBER:		251066671

	BUSINESS ADDRESS:	
		STREET 1:		700 SAGINAW DR
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		415-766-3638

	MAIL ADDRESS:	
		STREET 1:		700 SAGINAW DR
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d838043d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rvmdw="http://imetrix.edgar-online.com/20250623" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-483">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-06-23_to_2025-06-23">0001628171</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="rvmdw-20250623.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-06-23_to_2025-06-23"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001628171</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-06-23</xbrli:startDate> <xbrli:endDate>2025-06-23</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-CommonStock0.0001ParValuePerShareMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001628171</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rvmdw:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-06-23</xbrli:startDate> <xbrli:endDate>2025-06-23</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001628171</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rvmdw:WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-06-23</xbrli:startDate> <xbrli:endDate>2025-06-23</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-510">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-06-23_to_2025-06-23" format="ixt:datemonthdayyearen" id="ixv-511">June&#160;23, 2025</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-512">Revolution Medicines, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-06-23_to_2025-06-23" format="ixt-sec:stateprovnameen" id="ixv-513">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-514">001-39219</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-515">47-2029180</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-516">700 Saginaw Drive</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-517">Redwood City</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-06-23_to_2025-06-23" format="ixt-sec:stateprovnameen" id="ixv-518">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-519">94063</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-520">650</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-521">481-6801</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-06-23_to_2025-06-23" format="ixt-sec:boolballotbox" id="ixv-522">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-06-23_to_2025-06-23" format="ixt-sec:boolballotbox" id="ixv-523">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-06-23_to_2025-06-23" format="ixt-sec:boolballotbox" id="ixv-524">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-06-23_to_2025-06-23" format="ixt-sec:boolballotbox" id="ixv-525">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><br/>Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-CommonStock0.0001ParValuePerShareMember" id="ixv-526">Common Stock $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-CommonStock0.0001ParValuePerShareMember" id="ixv-527">RVMD</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-CommonStock0.0001ParValuePerShareMember" format="ixt-sec:exchnameen" id="ixv-528">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" id="ixv-529">Warrants to purchase 0.1112 shares of common stock expiring 2026</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" id="ixv-530">RVMDW</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" format="ixt-sec:exchnameen" id="ixv-531">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-06-23_to_2025-06-23" format="ixt-sec:boolballotbox" id="ixv-532">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;1.01 Entry into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Royalty Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;23, 2025 (the &#8220;Effective Date&#8221;), Revolution Medicines, Inc. (the &#8220;Company&#8221;) entered into a revenue participation right purchase and sale agreement (the &#8220;Royalty Purchase Agreement&#8221;) with Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Royalty Purchase Agreement, in exchange for an upfront payment of $250.0&#160;million, Royalty Pharma purchased from the Company the right to receive tiered revenue payments (the &#8220;Royalty Payments&#8221;) with respect to worldwide net product sales (&#8220;Net Sales&#8221;) in a calendar year (&#8220;Annual Net Sales&#8221;) of (a)&#160;the Company&#8217;s RAS(ON) multi-selective inhibitor, daraxonrasib (together with certain potential future products having the same mechanism of action as daraxonrasib, collectively, <span style="white-space:nowrap">&#8220;RMC-6236&#8221;)</span> and (b)&#160;the Company&#8217;s RAS(ON) G12D-selective inhibitor, zoldonrasib (together with certain potential future products having the same mechanism of action as zoldonrasib, <span style="white-space:nowrap">&#8220;RMC-9805&#8221;),</span> if <span style="white-space:nowrap">RMC-9805</span> is approved for the same indication or subset of the same indication for which <span style="white-space:nowrap">RMC-6236</span> is approved (collectively, the &#8220;Royalty-Bearing Products&#8221;). In addition, under the Royalty Purchase Agreement, (i)&#160;Royalty Pharma will purchase additional Royalty Payments from the Company in exchange for a payment of $250.0&#160;million (the &#8220;Tranche 2 Funding&#8221;), if, prior to January&#160;1, 2028, there is a positive data readout from RASolute 302, the ongoing Phase 3 registrational trial in the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;) showing that <span style="white-space:nowrap">RMC-6236</span> meets an agreed-upon endpoint in a statistically significant manner and the earlier of (A)&#160;the Company&#8217;s determination to proceed with the preparation and submission of a New Drug Application to the Food and Drug Administration (the &#8220;FDA&#8221;) on the basis of such readout or (B)&#160;the submission of a New Drug Application on the basis of such readout (collectively, the &#8220;Tranche 2 Trigger&#8221;) and (ii)&#160;in each case, at the Company&#8217;s election, the Company will sell and Royalty Pharma will purchase, additional Royalty Payments in exchange for (W)&#160;a payment of up to $250.0&#160;million (the &#8220;Tranche 3 Funding&#8221;), if, prior to July&#160;1, 2028, <span style="white-space:nowrap">RMC-6236</span> receives FDA approval for the second-line treatment of RAS <span style="white-space:nowrap">G12-mutated</span> metastatic PDAC or metastatic PDAC, (X)&#160;a payment of up to $250.0&#160;million (the &#8220;Tranche 4 Funding&#8221;), if the Company meets a specified Net Sales milestone for Royalty-Bearing Products prior to January&#160;1, 2029, (Y)&#160;a payment of up to $100.0&#160;million (the &#8220;Tranche 5 Sub Funding&#8221;), if prior to January&#160;1, 2030, there is a positive data readout from a potential Phase 3 clinical trial for the first-line treatment of metastatic PDAC involving either <span style="white-space:nowrap">(1)&#160;RMC-6236</span> or <span style="white-space:nowrap">(2)&#160;RMC-9805,</span> in each case, showing that the applicable Company compound meets an agreed-upon endpoint in a statistically significant manner and the FDA accepts a New Drug Application (or a supplemental application or an amendment to an existing application) on the basis of such readout, and (Z)&#160;a payment of up to the difference of (I) $250.0&#160;million and (II)&#160;the purchase price of any Royalty Payments purchased at Tranche 5 Sub Funding (the &#8220;Tranche 5 Funding&#8221;), if prior to January&#160;1, 2030, there is a positive data readout from a potential Phase 3 clinical trial for the first-line treatment of metastatic PDAC involving either <span style="white-space:nowrap">(1)&#160;RMC-6236</span> or <span style="white-space:nowrap">(2)&#160;RMC-9805,</span> in each case, showing that the applicable Company compound meets an agreed-upon endpoint in a statistically significant manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below summarizes the Royalty Payments (assuming each of the Tranche 2 Funding, the Tranche 3 Funding, the Tranche 4 Funding, the Tranche 5 Sub Funding and the Tranche 5 Fundings occurs up to the maximum amount available), based on the percentage of Annual Net Sales of the Royalty-Bearing Products. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:30%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center">Annual</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Net Sales</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Upfront<br/>Royalty</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Tranche&#160;2<br/>Royalty</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Tranche&#160;3<br/>Royalty</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Tranche&#160;4<br/>Royalty</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Tranche&#160;5<br/>Sub&#160;Royalty</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center">Tranche 5</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Royalty</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Total<br/>Royalty</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$0&#8211;$2 billion&#8194;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">0.45% (or 0.75% if no Tranche 5 Sub Funding)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; $2&#160;billion and &#8804; $4&#160;billion</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.20</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">0.30% (or 0.50% if no Tranche 5 Sub Funding)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; $4&#160;billion and &#8804; $8&#160;billion</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.60</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.40</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.40</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.20</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">0.30% (or 0.50% if no Tranche 5 Sub Funding)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.40</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company opts to sell Royalty Pharma a right to receive a portion of Annual Net Sales of the Royalty-Bearing Products that is less than the maximum permitted under the Royalty Purchase Agreement with respect to the Tranche 3 Funding, the Tranche 4 Funding, the Tranche 5 Sub Funding or the Tranche 5 Funding, then the applicable rates set forth above in respect of such Royalty Payments would be scaled down on a pro rata basis. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Royalty Purchase Agreement provides for an upward adjustment to the Royalty Payment rates in the years from 2030 to 2041 in the event that Annual Net Sales in the immediate prior year are below an agreed-upon threshold. This threshold was derived from <span style="white-space:nowrap"><span style="white-space:nowrap">return-on-investment</span></span> calculations and is in the lower end of the ranges described above. Any upward adjustment will revert to the original Royalty Payment rates in the event that Annual Net Sales are above a different agreed-upon threshold. The upward adjustment to the Royalty Payment rates applies only to the $0&#8211;$2&#160;billion Annual Net Sales tier, and the adjusted total Royalty Payment rate for this tier remains in the single digits. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Royalty Payments in respect of Annual Net Sales of <span style="white-space:nowrap">RMC-6236</span> in the United States will end 15 years after the first commercial sale of <span style="white-space:nowrap">RMC-6236</span> in the United States. The Royalty Payments (if any) in respect of Annual Net Sales of <span style="white-space:nowrap">RMC-9805</span> in the United States will end 15 years after the earlier to occur of (i)&#160;the date that <span style="white-space:nowrap">RMC-9805</span> is approved in an overlapping indication with <span style="white-space:nowrap">RMC-6236</span> in the United States and (ii)&#160;the first commercial sale of <span style="white-space:nowrap">RMC-6236</span> in the United States. The Royalty Payments in respect of Annual Net Sales of <span style="white-space:nowrap">RMC-6236</span> outside the United States will end 15 years after the first commercial sale of <span style="white-space:nowrap">RMC-6236</span> in the European Union. The Royalty Payments (if any) in respect of Annual Net Sales of <span style="white-space:nowrap">RMC-9805</span> outside the United States will end 15 years after the earlier to occur of (i)&#160;the date that <span style="white-space:nowrap">RMC-9805</span> is approved in an overlapping indication with <span style="white-space:nowrap">RMC-6236</span> in any country in the European Union and (ii)&#160;the first commercial sale of <span style="white-space:nowrap">RMC-6236</span> in the European Union. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, prior to the achievement of the Tranche 2 Trigger, the Company enters into a definitive agreement for a change of control, the Company will have the option to cancel the Tranche 2 Funding and the associated Royalty Payments. Royalty Pharma agrees to cooperate with the transfer of the Royalty Purchase Agreement to any acquiror in connection with a change of control of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Royalty Purchase Agreement contains customary representations, warranties and indemnities of the Company and Royalty Pharma, and customary covenants on the part of the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loan Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Effective Date, the Company also entered into a loan agreement (the &#8220;Loan Agreement&#8221; and, together with the Royalty Purchase Agreement, the &#8220;Strategic Financing Agreements&#8221;) with Wilmington Trust, National Association, as administrative agent (the &#8220;Agent&#8221;), and Royalty Pharma Development Funding, LLC, as a lender (the &#8220;Lender&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Loan Agreement provides for a term loan facility of up to $750.0&#160;million (the &#8220;Term Loan Facility&#8221;), consisting of three tranches, one of which must be drawn and the other two of which may be drawn at the Company&#8217;s option during certain commitment periods, subject to the satisfaction or waiver of certain terms and conditions: (i)&#160;a tranche in an aggregate principal amount of $250.0&#160;million (the &#8220;Tranche A Loans&#8221; and the date on which the Tranche A Loans are funded, the &#8220;Tranche A Funding Date&#8221;), which is required to be drawn in whole in a single draw by the Company within 45 days of its receipt of marketing approval from the FDA for daraxonrasib for any indication or treatment related to metastatic PDAC, if such approval is received on or prior to January&#160;1, 2028 unless the Company has previously elected to terminate the Term Loan Facility (as further described below); (ii) a tranche in an aggregate principal amount up to $250.0&#160;million (the &#8220;Tranche B Loans&#8221; and the date on which the Tranche&#160;B Loans are funded, the &#8220;Tranche B Funding Date&#8221;), which the Company may elect to borrow in a single draw (in whole or in part), within 45 days of the date the Agent receives certification of the Company&#8217;s achievement of a specified Net Sales milestone, if this milestone is achieved prior to January&#160;1, 2028; and (iii)&#160;a tranche in an aggregate principal amount up to $250.0&#160;million (the &#8220;Tranche C Loans&#8221; and, together with the Tranche A Loans and the Tranche B Loans, the &#8220;Term Loans&#8221; and the date on which the Tranche C Loans are funded, and, together with the Tranche A Funding Date and the Tranche B Funding Date, each, a &#8220;Funding Date&#8221;), which the Company may elect to borrow in a single draw (in whole or in part), within 45 days of the date the Agent receives certification of the Company&#8217;s achievement of a specified Net Sales milestone, if this milestone is achieved prior to January&#160;1, 2028. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Term Loan Facility matures on the earlier of (i)&#160;the six year anniversary of the Tranche A Funding Date and (ii)&#160;December 31, 2032 (such earlier date, the &#8220;Maturity Date&#8221;), and the Term Loans thereunder bear interest at a floating per annum rate equal to (a)&#160;the three-month term SOFR (subject to a 3.50% floor) plus (b) 5.75%, payable on a quarterly basis. The Term Loan Facility has no scheduled amortization payments prior to the Maturity Date. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On each Funding Date, the Company is required to pay the Lender an upfront fee equal to 2.00% of the Term Loans drawn on such Funding Date. In addition, the Loan Agreement requires the Company to make prepayments in the event of a change of control and permits the Company to make voluntary prepayments in whole. Principal prepayments in respect of the Term Loans will be subject to, with respect to each tranche of the Term Loans, (i)&#160;prior to the second anniversary of the Funding Date of such tranche of Term Loans, a make-whole premium in an amount equal to the sum of all interest that would have accrued and been payable from such prepayment date to (but excluding) such second anniversary plus (ii)&#160;a prepayment premium equal to either (a) 3.00% of such tranche of Term Loans, for prepayments prior to the third anniversary of the Funding Date of such tranche of Term Loans or (b) 1.00% of such tranche of Term Loans, for prepayments on or after the third anniversary of the Funding Date of such tranche of Term Loans. For the avoidance of doubt, no make-whole premium or prepayment premium shall be due and payable if the Term Loans are repaid on the Maturity Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should a change of control of the Company occur prior to the Tranche A Funding Date, or the Company elects to terminate the Term Loan Facility prior to the Tranche A Funding Date, the Company is required to pay the Lender a sum equal to: (i) 1.00% of the Tranche A Loans, plus (ii)&#160;the make-whole premium and prepayment premium with respect to the Tranche A Loans, calculated as if the full amount of the Tranche A Loans were drawn on the date on which the change in control was consummated or the date the Company elected to terminate the Term Loan Facility, as applicable. If the Company does not draw the Tranche A Loans within 45 days of its receipt of marketing approval from the FDA for daraxonrasib for any indication or treatment related to metastatic PDAC, then the Company will be required to pay the Lender a sum equal to: (i) 1.00% of the Tranche A Loans, plus (ii)&#160;the make-whole premium and prepayment premium with respect to the Tranche A Loans, calculated as if the full amount of the Tranche A Loans were drawn on the 45th day following its receipt of such FDA approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Term Loan Facility will be guaranteed by certain of the Company&#8217;s existing and future subsidiaries (collectively, the &#8220;Guarantors&#8221;), and the obligations of the Company and the Guarantors under the Term Loan Facility will be secured by security interests in, and pledges over, substantially all of the assets of the Company and the Guarantors (including, without limitation, capital stock, material bank accounts and intercompany receivables), in each case, subject to certain agreed security principles, permitted liens and other customary exceptions and qualifications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Loan Agreement contains customary covenants that limit the Company&#8217;s and its subsidiaries&#8217; ability to, among other activities (but subject to certain customary exceptions): (i) pay dividends, redeem stock or make other distributions or investments; (ii)&#160;incur additional debt; (iii)&#160;transfer or sell assets; (iv)&#160;create liens; (v)&#160;engage in certain transactions with affiliates; (vi)&#160;create restrictions on dividends or other payments by the Company&#8217;s subsidiaries; and (vii)&#160;merge, consolidate or effect other fundamental changes. The Loan Agreement does not include any financial covenants. The Loan Agreement also includes certain customary affirmative covenants, including financial reporting, notice obligations, and requirements to grant and provide guarantees and securities interest in respect of property and assets acquired from time to time after the Effective Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Loan Agreement provides an enumerated list of customary events of default, including, without limitation, payment defaults, breach of representations and warranties, covenant defaults, cross-defaults to certain material agreements and certain indebtedness, certain events of bankruptcy, material judgments, and the occurrence of a material adverse change. If an event of default occurs under the Loan Agreement, the Agent, for and on behalf of the Lender, will be entitled to exercise remedial rights and powers and take various actions (including, without limitation, (i)&#160;the acceleration of all amounts due under the Term Loan Facility; (ii)&#160;the application of default rate interest; (iii)&#160;the exercise of powers of attorney, voting proxies and other similar rights; (iv)&#160;the foreclosure and sale of property and assets and (v)&#160;other actions permitted to be taken by a secured creditor). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the Strategic Financing Agreements do not purport to be complete and are qualified in their entirety by reference to such agreements, copies of which the Company expects to file, with certain confidential terms redacted, as exhibits to its Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ending June&#160;30, 2025. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;2.03 Creation of a Direct Financial Obligation or an Obligation under an <span style="white-space:nowrap">Off-Balance</span> Sheet Arrangement of a Registrant. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under Item 1.01 above is incorporated by reference into this Item 2.03. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Press Release </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;24, 2025, the Company issued a press release announcing the Strategic Financing Agreements, a copy of which is furnished as Exhibit 99.1 to this report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Supplemental Financial Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of entering into the transactions described in Item 1.01 of this report, the Company is removing its cash runway end date guidance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to 2025 GAAP net loss guidance, the Company is in the process of evaluating the appropriate accounting treatment of the facility described in this report and also evaluating the impact of the decision to pursue independent global development and commercialization. Accordingly, the Company is withdrawing its previous guidance on expected 2025 GAAP net loss and expects to provide updated financial guidance in the Company&#8217;s second quarter 2025 earnings release. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished under this Item 7.01 and in the accompanying Exhibit 99.1 to this report shall be deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933 (the &#8220;Securities Act&#8221;), and shall not be incorporated by reference into any filing made by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cautionary Statement Regarding Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report includes &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made in this report that are not historical facts may be considered forward-looking statements, including, without limitation, statements regarding the Strategic Financing Agreements (including with respect to potential trigger events, tranche loans and royalty payments), and the Company&#8217;s decision to pursue independent global development and commercialization. Forward-looking statements are typically, but not always, identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the Company&#8217;s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the Company&#8217;s programs&#8217; current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company&#8217;s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the Company&#8217;s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the Company&#8217;s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed with the SEC on May&#160;7, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d838043dex991.htm">Press Release, dated June&#160;24, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">REVOLUTION MEDICINES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;24, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark A. Goldsmith</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark A. Goldsmith, M.D., Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d838043dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g838043g0624072140673.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development
and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with <FONT STYLE="white-space:nowrap">RAS-Addicted</FONT> Cancers </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Flexible funding provides $2&nbsp;billion in committed capital comprised of up to $1.25&nbsp;billion of synthetic
royalty and up to $750&nbsp;million in corporate debt </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Company moving forward with independent global commercialization strategy to prioritize patient reach and
maximize shareholder value </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Transaction expands Revolution Medicines&#146; financial resources and optionality with $1.25&nbsp;billion of the
$2&nbsp;billion available at the company&#146;s discretion </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Revolution Medicines to host webcast today at 8:00 a.m. Eastern Time </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REDWOOD CITY, Calif., June</B><B></B><B>&nbsp;24, 2025</B> (GLOBE NEWSWIRE) &#150; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical
oncology company developing targeted therapies for patients with <FONT STYLE="white-space:nowrap">RAS-addicted</FONT> cancers, today announced that it has partnered with Royalty Pharma on $2&nbsp;billion in flexible funding to support Revolution
Medicines&#146; independent global development and commercialization strategy and operations. Revolution Medicines retains full strategic and executional control of product development and commercialization for its portfolio of RAS(ON) inhibitors in
the US and internationally, enabling the company to leverage its assets, capabilities and momentum toward establishing new global standards of care and creating value for shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Today&#146;s announcement represents a major boost to our bold vision on behalf of patients with <FONT STYLE="white-space:nowrap">RAS-addicted</FONT>
cancers,&#148; said Mark A. Goldsmith M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. &#147;This funding agreement significantly increases the financial resources we can deploy while preserving optionality as we scale our
operations to create the industry-leading global targeted medicines franchise for patients with <FONT STYLE="white-space:nowrap">RAS-addicted</FONT> cancers based on our highly differentiated RAS(ON) inhibitor portfolio.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to announce today a groundbreaking partnership that provides Revolution Medicines with up to $2&nbsp;billion of long-term capital through
a customized funding solution that facilitates the expansive development and global commercialization of its leading RAS(ON) inhibitor portfolio,&#148; said Pablo Legorreta, founder and chief executive officer of Royalty Pharma. &#147;This
partnership exemplifies a new funding paradigm for highly innovative biotech companies. In contrast to a conventional pharma partnership, this large scale and flexible funding agreement enables Revolution Medicines to retain control of the clinical
development of daraxonrasib, as well as the ability to capture significant value creation that would result from the successful clinical development and commercialization of its pipeline.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The funding agreement provides for $2&nbsp;billion in committed capital comprised of up to $1.25&nbsp;billion in synthetic royalty monetization on sales of
daraxonrasib, the company&#146;s RAS(ON) multi-selective inhibitor, and up to $750&nbsp;million in corporate debt. The agreement provides significant flexibility to Revolution Medicines with $1.25&nbsp;billion of the total funding reserved as
optional to the company at its discretion, subject to the achievement of specific milestones. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Synthetic royalty details </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Royalty Pharma will provide up to $1.25&nbsp;billion in exchange for tiered royalties for a term of 15 years on
worldwide annual net sales of daraxonrasib; the royalties decrease based on sales and for sales above $8&nbsp;billion the royalty rate is zero.</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The $1.25&nbsp;billion synthetic royalty funding is divided into five tranches of $250&nbsp;million.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The first two $250&nbsp;million tranches, totaling $500&nbsp;million, are payable prior to daraxonrasib&#146;s
approval by the FDA and royalty obligations begin only after daraxonrasib approval. Revolution Medicines received the first $250&nbsp;million tranche at closing and the second $250&nbsp;million tranche is due to the company upon a positive data
readout from the company&#146;s RASolute 302 study, a global Phase 3 trial in patients with previously treated pancreatic ductal adenocarcinoma (PDAC). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The royalty rates on annual net sales for these two tranches are 4.55% on the first $2&nbsp;billion, 2.50% on
$2&nbsp;billion to $4&nbsp;billion, 1.00% on $4&nbsp;billion to $8&nbsp;billion and zero above $8&nbsp;billion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At annual net sales of $8&nbsp;billion, the effective blended royalty rate for these tranches would be 2.26% and
this rate progressively decreases as net sales increase above $8&nbsp;billion. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The subsequent three equal tranches, totaling $750&nbsp;million, are post-approval tranches that can be drawn at
the company&#146;s discretion after certain milestones are achieved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a scenario where the company draws the entire $1.25 billion: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The royalty rates for all five tranches on annual net sales are 7.80% on the first $2&nbsp;billion, 4.55% on
$2&nbsp;billion to $4&nbsp;billion, 2.40% on $4&nbsp;billion to $8&nbsp;billion and zero above $8&nbsp;billion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At annual net sales of $8&nbsp;billion, the effective blended royalty rate would be 4.29% and this rate
progressively decreases as net sales increase above $8&nbsp;billion. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential exists for overlapping indication labels across certain assets within the company&#146;s pipeline.
If zoldonrasib, the company&#146;s RAS(ON) G12D-selective inhibitor, were approved in the same indication as daraxonrasib, zoldonrasib sales would be included in the calculation of total net sales that are subject to the royalty schedule noted
above. If zoldonrasib is approved solely for indications outside of daraxonrasib indications, zoldonrasib sales would not be subject to any royalties under the royalty agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt details </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The debt facility is an up to $750&nbsp;million senior secured term loan consisting of three $250&nbsp;million
tranches linked to commercialization of daraxonrasib. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The company would receive the first debt tranche of $250&nbsp;million following first FDA approval of
daraxonrasib for the treatment of metastatic PDAC, if this occurs by January&nbsp;1, 2028. Debt tranches two and three are optional at the company&#146;s discretion and will be available to the company based on achievement of annual net sales
milestones for daraxonrasib. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The term loan is an interest-only facility, with principal due at the earlier of (i) 6 years after the first
tranche is funded and (ii)&nbsp;December&nbsp;31, 2032. The interest rate is calculated based on the <FONT STYLE="white-space:nowrap">3-month</FONT> Standard Overnight Financing Rate (SOFR) plus 5.75%, with a SOFR floor of 3.50%.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further details on this transaction can be found in the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed by the
company today with the Securities and Exchange Commission. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash runway update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of entering into this funding agreement with Royalty Pharma, the company is removing its cash runway end date guidance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor webcast </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revolution Medicines management will
host an investor webcast today, June&nbsp;24, at 8:00&nbsp;a.m. ET (5:00 a.m. PT) to discuss this transaction. To participate in the live webcast, participants may register at <U>https://edge.media-server.com/mmc/p/b35x58yh</U>. A live webcast of
the call will be available on the Investors section of Revolution Medicines&#146; website at&nbsp;<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://ir.revmed.com/events-and-presentations</FONT></FONT></U>. Following the
live webcast, a replay will be available on the company&#146;s website for at least 14 days. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advisors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD Securities acted as financial advisor and Latham&nbsp;&amp; Watkins acted as legal advisor to Revolution Medicines. Goodwin Procter and Maiwald acted as
legal advisors to Royalty Pharma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Revolution Medicines, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with
<FONT STYLE="white-space:nowrap">RAS-addicted</FONT> cancers. The company&#146;s R&amp;D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company&#146;s RAS(ON) inhibitors daraxonrasib <FONT
STYLE="white-space:nowrap">(RMC-6236),</FONT> a RAS(ON) multi-selective inhibitor; elironrasib <FONT STYLE="white-space:nowrap">(RMC-6291),</FONT> a RAS(ON) G12C-selective inhibitor; and zoldonrasib
<FONT STYLE="white-space:nowrap">(RMC-9805),</FONT> a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that <FONT STYLE="white-space:nowrap">RMC-5127,</FONT> a RAS(ON) G12V-selective inhibitor, will be
its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company&#146;s pipeline focus on RAS(ON) mutant-selective inhibitors, including <FONT STYLE="white-space:nowrap">RMC-0708</FONT> (Q61H) and <FONT
STYLE="white-space:nowrap">RMC-8839</FONT> (G13C). For more information, please visit <U>www.revmed.com</U> and follow us on <U>LinkedIn</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward
Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act
of 1995. Any statements in this press release that are not historical facts may be considered &#147;forward-looking statements,&#148; including without limitation statements regarding the potential for daraxonrasib, zoldonrasib or other assets
within the company&#146;s pipeline to be approved by the FDA, including the indications for which they are approved; the company&#146;s development and commercialization plans for its RAS(ON) inhibitor portfolio; the company&#146;s priorities
regarding standards of care, patient reach and shareholder value; its vision on behalf of patients with <FONT STYLE="white-space:nowrap">RAS-addicted</FONT> cancers; the financial resources available to the company, including the availability of
capital from the synthetic royalty and the corporate debt arrangement and whether the company achieves the milestones associated with certain payments thereunder; and whether the company elects to receive optional funding under the arrangement, if
available. Forward-looking statements are typically, but not always, identified by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;believe,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;anticipate,&#148;
&#147;estimate,&#148; &#147;expect,&#148; and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company&#146;s development programs, future
results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including
the company&#146;s programs&#146; current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical
efficacy, or other future results, the regulatory approval </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>processes, the timing of regulatory filings, the challenges associated with manufacturing drug products,
the company&#146;s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company&#146;s capital resources to fund operations, reliance on third parties for
manufacturing and development efforts, changes in the competitive landscape, and the effects on the company&#146;s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and
uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of the company in general, see the company&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> filed with the Securities and Exchange Commission (the SEC) on May&nbsp;7, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, the company undertakes no obligation to
update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revolution Medicines Media&nbsp;&amp; Investor Contact: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@revmed.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investors@revmed.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rvmdw-20250623.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/24/2025 8:03:28 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:rvmdw="http://imetrix.edgar-online.com/20250623"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://imetrix.edgar-online.com/20250623"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" namespace="http://fasb.org/us-types/2024" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvmdw-20250623_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvmdw-20250623_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvmdw-20250623_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rvmdw_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rvmdw_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rvmdw_CommonStock0.0001ParValuePerShareMember" name="CommonStock0.0001ParValuePerShareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" name="WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>rvmdw-20250623_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/24/2025 8:03:32 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rvmdw-20250623.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="rvmdw_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="rvmdw_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_CommonStock0.0001ParValuePerShareMember" xlink:type="locator" xlink:label="rvmdw_CommonStock0.0001ParValuePerShareMember" />
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" xlink:type="locator" xlink:label="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="rvmdw_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rvmdw_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rvmdw_CommonStock0.0001ParValuePerShareMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="27.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="31.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="32.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="33.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="50.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rvmdw-20250623_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/24/2025 8:03:28 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="rvmdw_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvmdw_DocumentAndEntityInformationTable" xlink:to="rvmdw_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rvmdw_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="rvmdw_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="rvmdw_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="rvmdw_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="rvmdw_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rvmdw_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_CommonStock0.0001ParValuePerShareMember" xlink:type="locator" xlink:label="rvmdw_CommonStock0.0001ParValuePerShareMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvmdw_CommonStock0.0001ParValuePerShareMember" xlink:to="rvmdw_CommonStock0.0001ParValuePerShareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rvmdw_CommonStock0.0001ParValuePerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock 0.0001 Par Value Per Share [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rvmdw_CommonStock0.0001ParValuePerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock 0.0001 Par Value Per Share [Member]</link:label>
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" xlink:type="locator" xlink:label="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" xlink:to="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rvmdw-20250623_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/24/2025 8:03:29 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rvmdw-20250623.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="rvmdw_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="rvmdw_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="rvmdw_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationTable" xlink:to="rvmdw_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_CommonStock0.0001ParValuePerShareMember" xlink:type="locator" xlink:label="rvmdw_CommonStock0.0001ParValuePerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rvmdw_CommonStock0.0001ParValuePerShareMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="rvmdw-20250623.xsd#rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" xlink:type="locator" xlink:label="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvmdw_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g838043g0624072140673.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838043g0624072140673.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& -H# 2(  A$! Q$!_\0
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M[K)U'P;]AE8^=ITIB(/78?F7^H_X#7F'BLGQ3J?BGQ%N)M;%XH(/0Y<(N/\
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MA73T447!))604444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 23, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rvmdw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 23,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Revolution Medicines, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2029180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 Saginaw Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-6801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rvmdw_CommonStock0.0001ParValuePerShareMember', window );">Common Stock 0.0001 Par Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rvmdw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RVMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member', window );">Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rvmdw_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Warrants to purchase 0.1112 shares of common stock expiring 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RVMDW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvmdw_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvmdw_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvmdw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rvmdw_CommonStock0.0001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rvmdw_CommonStock0.0001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d838043d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d838043d8k.htm">d838043d8k.htm</File>
    <File>rvmdw-20250623.xsd</File>
    <File>rvmdw-20250623_def.xml</File>
    <File>rvmdw-20250623_lab.xml</File>
    <File>rvmdw-20250623_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d838043d8k.htm": {
   "nsprefix": "rvmdw",
   "nsuri": "http://imetrix.edgar-online.com/20250623",
   "dts": {
    "inline": {
     "local": [
      "d838043d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "rvmdw-20250623.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "rvmdw-20250623_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rvmdw-20250623_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rvmdw-20250623_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-06-23_to_2025-06-23",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d838043d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-06-23_to_2025-06-23",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d838043d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "rvmdw_CommonStock0.0001ParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://imetrix.edgar-online.com/20250623",
     "localname": "CommonStock0.0001ParValuePerShareMember",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock 0.0001 Par Value Per Share [Member]",
        "terseLabel": "Common Stock 0.0001 Par Value Per Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "rvmdw_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://imetrix.edgar-online.com/20250623",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "rvmdw_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://imetrix.edgar-online.com/20250623",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "rvmdw_WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://imetrix.edgar-online.com/20250623",
     "localname": "WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]",
        "terseLabel": "Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://imetrix.edgar-online.com//20250623/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-145242-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-145242-xbrl.zip
M4$L#!!0    ( *DXV%KR@H/Y""<  .+I   .    9#@S.# T,V0X:RYH=&WM
M?6E3XTC2\/?^%17>F5V(L(TO:*[F"1KH67:[H1]@=N9]ODR4I;*M;5G2EB3
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MZI=I^<$HKS66F $":'Z*0LGP\UED"]Q@\5@@(1OC%-V#;D9AEL"1;A&;2H^
MN_[^=-#UJD!7V'A-ZRRV%5&L/L2@9]!\\6 - F*6")G+5_=@'?]OSCK )EUF
M'=OL.NU7KF7.X-W6LDR=YQ01P\8=V&UD;YJ!&U08>#).*C"AO*-> &8/J3#"
M([UGL>^O;:1I"3?#93[NY#Y&]233:0I,H2 8])$39$^8D&-0 KU*(8!ZI7*
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M?*SZ#S^"0CY3A/GM"1[R7>9TQ=3QIU6E8ND<OJE,+/HF*.?#29[ PO'DR@
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M*^PM;_2J<.4;Q@%I6?:N-+TCRFN+V3NE#XB=:8$?H1-616"@N=[2J0'L S'
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M= N[^*JKL'(T,(4HFN$"JRCC;.Y-_A*PM2#P4M=M5$(7/:\KVO6J:MZ'G(U
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M$C3[-E"ZT<?6]6,,"Y_)G*HA.4X^>9&UH\VYK8X*)4)8>8S[H&#"PYT3'AA
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M,#0S9&5X.3DQ+FAT;5!+ 0(4 Q0    ( *DXV%H7BS^!1@0  'D1   2
M          "  7,\  !R=FUD=RTR,#(U,#8R,RYX<V102P$"% ,4    " "I
M.-A:RA7 N?,%  "O-   %@              @ 'I0   <G9M9'<M,C R-3 V
M,C-?9&5F+GAM;%!+ 0(4 Q0    ( *DXV%JN=@/X @@  *97   6
M      "  1!'  !R=FUD=RTR,#(U,#8R,U]L86(N>&UL4$L! A0#%     @
MJ3C86@2[),VS!0  .3@  !8              ( !1D\  ')V;61W+3(P,C4P
A-C(S7W!R92YX;6Q02P4&      8 !@"' 0  +54

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d838043d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rvmdw="http://imetrix.edgar-online.com/20250623"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rvmdw-20250623.xsd" xlink:type="simple"/>
    <context id="duration_2025-06-23_to_2025-06-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628171</identifier>
        </entity>
        <period>
            <startDate>2025-06-23</startDate>
            <endDate>2025-06-23</endDate>
        </period>
    </context>
    <context id="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-CommonStock0.0001ParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628171</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rvmdw:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-23</startDate>
            <endDate>2025-06-23</endDate>
        </period>
    </context>
    <context id="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628171</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rvmdw:WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-23</startDate>
            <endDate>2025-06-23</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-483">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-06-23_to_2025-06-23"
      id="Hidden_dei_EntityCentralIndexKey">0001628171</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-510">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-511">2025-06-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-512">Revolution Medicines, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-513">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-514">001-39219</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-515">47-2029180</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-516">700 Saginaw Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-517">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-518">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-519">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-520">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-521">481-6801</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-522">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-523">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-524">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-525">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-CommonStock0.0001ParValuePerShareMember"
      id="ixv-526">Common Stock $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-CommonStock0.0001ParValuePerShareMember"
      id="ixv-527">RVMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-CommonStock0.0001ParValuePerShareMember"
      id="ixv-528">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member"
      id="ixv-529">Warrants to purchase 0.1112 shares of common stock expiring 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member"
      id="ixv-530">RVMDW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-06-23_to_2025-06-23_us-gaap-StatementClassOfStockAxis_rvmdw-WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member"
      id="ixv-531">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-06-23_to_2025-06-23" id="ixv-532">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
